Thrombotic thrombocytopenic purpura following administration of the Moderna booster vaccine

Area of Science:

• Hematology
• Immunology
• Vaccinology

Background:

• Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening thrombotic microangiopathy.
• TTP results from severe deficiency of ADAMTS13 enzyme activity, leading to platelet aggregation and microvascular thrombosis.
• Acquired TTP has diverse triggers, including medications, infections, and, rarely, vaccines.

Observation:

• A case of TTP is presented following the administration of a Moderna COVID-19 booster vaccine.
• The patient developed symptoms consistent with TTP post-vaccination.
• This highlights a potential, albeit rare, adverse event associated with novel vaccine technologies.

Findings:

• The patient's TTP was potentially linked to the Moderna booster vaccine.
• Investigating vaccine-associated TTP is crucial for patient safety and vaccine development.
• Prompt diagnosis and treatment of TTP are essential for patient outcomes.

Implications:

• Heightened awareness among healthcare providers regarding vaccine-associated TTP is necessary.
• Further research into the immunological mechanisms linking vaccines to TTP is warranted.
• This case underscores the importance of pharmacovigilance for new vaccines during global health crises.